IPS-3 Validation in 1012 cases with classical hodgkin lymphoma. (March 2021)
- Record Type:
- Journal Article
- Title:
- IPS-3 Validation in 1012 cases with classical hodgkin lymphoma. (March 2021)
- Main Title:
- IPS-3 Validation in 1012 cases with classical hodgkin lymphoma
- Authors:
- Paydas, Semra
Laçin, Sahin
Doğan, Mutlu
Barista, Ibrahim
Yildiz, Birol
Seydaoglu, Gulsah
Karadurmus, Nuri
Civriz, Sinem
Kaplan, Muhammed Ali
Yagci, Munci
Gurkan, Emel
Ercolak, Vehbi - Abstract:
- Highlights: HL is one of the rare curable entities in adults with 80% long term survival chance and risk scoring before planning the management of the patients is very important. There is significant improvement both in diagnostic imaging modalities including PET/CT and also treatments including targeted and immunotherapeutic approaches for this unique entity. Despite these significant improvement in outcomes, 20% of the patients have refractory disease or show relapse. Clinicians need an ideal scoring system to identify the risk of every patient and the most commonly used clinical scoring system for a long time for this aim in cHL is IPS-7 and this scoring system has been replaced by IPS-3 system. Here it has been reported IPS-3 scoring system has been evaluated and validated in 1012 cases. Abstract: The aim of this study is to validate the IPS-3 scoring system as a prognostic indicator in 1012 patients with advanced stage classical Hodgkin Lymphoma (cHL) treated by doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD). According to the IPS-3 scoring system only 3.5 % had high risk and 50.8 % had low risk disease disease and 45.8 % of the cases had intermediate risk disease. Each factors of IPS-7 and IPS-3 scoring systems (age, sex, stage hemoglobin, albumin, lymphocyte count and white cell count) were found to be significant for overall survival (OS) and progression free survival (PFS) according to univariate analyses. Two different multivariate Cox analyses wereHighlights: HL is one of the rare curable entities in adults with 80% long term survival chance and risk scoring before planning the management of the patients is very important. There is significant improvement both in diagnostic imaging modalities including PET/CT and also treatments including targeted and immunotherapeutic approaches for this unique entity. Despite these significant improvement in outcomes, 20% of the patients have refractory disease or show relapse. Clinicians need an ideal scoring system to identify the risk of every patient and the most commonly used clinical scoring system for a long time for this aim in cHL is IPS-7 and this scoring system has been replaced by IPS-3 system. Here it has been reported IPS-3 scoring system has been evaluated and validated in 1012 cases. Abstract: The aim of this study is to validate the IPS-3 scoring system as a prognostic indicator in 1012 patients with advanced stage classical Hodgkin Lymphoma (cHL) treated by doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD). According to the IPS-3 scoring system only 3.5 % had high risk and 50.8 % had low risk disease disease and 45.8 % of the cases had intermediate risk disease. Each factors of IPS-7 and IPS-3 scoring systems (age, sex, stage hemoglobin, albumin, lymphocyte count and white cell count) were found to be significant for overall survival (OS) and progression free survival (PFS) according to univariate analyses. Two different multivariate Cox analyses were performed for OS and PFS including the IPS-3/ IPS-7 scoring system parameters. Among 7 risk factors of IPS scoring system, gender and albumin were not found as independent risk factors for both OS and PFS according to cox regression model. But all parameters such as age, stage and hemoglobin those included in IPS-3, were found to be independent significant risk factors for both models obtained for OS and PFS. The results of the study shows that the IPS-3 scoring system can be used as a prognostic indicator in ABVD treated patients in every day practice which is more easily calculate according to the IPS-7. … (more)
- Is Part Of:
- Leukemia research. Volume 102(2021)
- Journal:
- Leukemia research
- Issue:
- Volume 102(2021)
- Issue Display:
- Volume 102, Issue 2021 (2021)
- Year:
- 2021
- Volume:
- 102
- Issue:
- 2021
- Issue Sort Value:
- 2021-0102-2021-0000
- Page Start:
- Page End:
- Publication Date:
- 2021-03
- Subjects:
- IPS-3 -- Hodgkin lymphoma -- Validation -- Survival
Leukemia -- Periodicals
Leukemia -- Periodicals
Leucémie -- Périodiques
Leukemia
Periodicals
Electronic journals
Electronic journals
616.9941905 - Journal URLs:
- http://www.sciencedirect.com/science/journal/01452126 ↗
http://www.elsevier.com/journals ↗ - DOI:
- 10.1016/j.leukres.2021.106519 ↗
- Languages:
- English
- ISSNs:
- 0145-2126
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 5185.270000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 15936.xml